Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints

Stephanie D. Davis, Margaret Rosenfeld, Gwendolyn S. Kerby, Lyndia Brumback, Margaret H. Kloster, James D. Acton, Andrew Colin, Carol K. Conrad, Meeghan A. Hart, Peter W. Hiatt, Peter J. Mogayzel, Robin C. Johnson, Stephanie L. Wilcox, Robert G. Castile

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Rationale: The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures. Objectives: To evaluate safety, feasibility, and ability to detect abnormalities in lung function of serial pulmonary function tests (PFTs) in infants with CF. Methods:Multicenter observational study using a commercial device, rigorous training, ongoing quality control, and over-reading of data by an independent panel. Raised volume rapid thoracoabdominal compression technique and plethysmography were performed at enrollment and at 6 and 12 months, with an additional 1-month reproducibility visit. Measurements and Main Results: A total of 342 procedures were performed in 100 infants with CF at 10 centers. FRC measurements were acceptable at a higher proportion of study visits (89%) than raised volume (72%) or fractional lung volume (68%) measurements. Average Z scores for many parameters differed significantly from historical control values. Mean (95% confidence interval) Z scores were: -0.52 (-0.78 to -0.25) for forced expiratory flow at 75% (FEF75) for FVC; 1.92 (1.39-2.45) for FRC; 1.22 (0.68-1.76) for residual volume; 0.87 (0.60-1.13) for FRC/total lung capacity; and 0.66 (0.27-1.06) for residual volume/total lung capacity. For future multicenter clinical trials using infant PFTs as primary endpoints, minimum detectable treatment effects are presented for several sample sizes. Conclusions: In this 10-center study, key PFT measures were significantly different in infants with CF than in historical control subjects. However, infant PFTs do not yet appear ready as primary efficacy endpoints for multicenter clinical trials, particularly at inexperienced sites, based on acceptability rates, variability, and potentially large sample sizes required to detect reasonable treatment effects.

Original languageEnglish
Pages (from-to)1387-1397
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume182
Issue number11
DOIs
StatePublished - Dec 1 2010

Fingerprint

Respiratory Function Tests
Cystic Fibrosis
Clinical Trials
Multicenter Studies
Total Lung Capacity
Residual Volume
Sample Size
Lung Volume Measurements
Plethysmography
Quality Control
Observational Studies
Reading
Outcome Assessment (Health Care)
Confidence Intervals
Safety
Equipment and Supplies
Lung
Therapeutics

Keywords

  • FEV
  • Forced expiratory flow rates
  • Longitudinal studies
  • Outcome assessment
  • Plethysmography

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Davis, S. D., Rosenfeld, M., Kerby, G. S., Brumback, L., Kloster, M. H., Acton, J. D., ... Castile, R. G. (2010). Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. American Journal of Respiratory and Critical Care Medicine, 182(11), 1387-1397. https://doi.org/10.1164/rccm.200908-1236OC

Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. / Davis, Stephanie D.; Rosenfeld, Margaret; Kerby, Gwendolyn S.; Brumback, Lyndia; Kloster, Margaret H.; Acton, James D.; Colin, Andrew; Conrad, Carol K.; Hart, Meeghan A.; Hiatt, Peter W.; Mogayzel, Peter J.; Johnson, Robin C.; Wilcox, Stephanie L.; Castile, Robert G.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 182, No. 11, 01.12.2010, p. 1387-1397.

Research output: Contribution to journalArticle

Davis, SD, Rosenfeld, M, Kerby, GS, Brumback, L, Kloster, MH, Acton, JD, Colin, A, Conrad, CK, Hart, MA, Hiatt, PW, Mogayzel, PJ, Johnson, RC, Wilcox, SL & Castile, RG 2010, 'Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints', American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 11, pp. 1387-1397. https://doi.org/10.1164/rccm.200908-1236OC
Davis, Stephanie D. ; Rosenfeld, Margaret ; Kerby, Gwendolyn S. ; Brumback, Lyndia ; Kloster, Margaret H. ; Acton, James D. ; Colin, Andrew ; Conrad, Carol K. ; Hart, Meeghan A. ; Hiatt, Peter W. ; Mogayzel, Peter J. ; Johnson, Robin C. ; Wilcox, Stephanie L. ; Castile, Robert G. / Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 182, No. 11. pp. 1387-1397.
@article{4bb953e3f8f94a2aa76be7983a05291c,
title = "Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints",
abstract = "Rationale: The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures. Objectives: To evaluate safety, feasibility, and ability to detect abnormalities in lung function of serial pulmonary function tests (PFTs) in infants with CF. Methods:Multicenter observational study using a commercial device, rigorous training, ongoing quality control, and over-reading of data by an independent panel. Raised volume rapid thoracoabdominal compression technique and plethysmography were performed at enrollment and at 6 and 12 months, with an additional 1-month reproducibility visit. Measurements and Main Results: A total of 342 procedures were performed in 100 infants with CF at 10 centers. FRC measurements were acceptable at a higher proportion of study visits (89{\%}) than raised volume (72{\%}) or fractional lung volume (68{\%}) measurements. Average Z scores for many parameters differed significantly from historical control values. Mean (95{\%} confidence interval) Z scores were: -0.52 (-0.78 to -0.25) for forced expiratory flow at 75{\%} (FEF75) for FVC; 1.92 (1.39-2.45) for FRC; 1.22 (0.68-1.76) for residual volume; 0.87 (0.60-1.13) for FRC/total lung capacity; and 0.66 (0.27-1.06) for residual volume/total lung capacity. For future multicenter clinical trials using infant PFTs as primary endpoints, minimum detectable treatment effects are presented for several sample sizes. Conclusions: In this 10-center study, key PFT measures were significantly different in infants with CF than in historical control subjects. However, infant PFTs do not yet appear ready as primary efficacy endpoints for multicenter clinical trials, particularly at inexperienced sites, based on acceptability rates, variability, and potentially large sample sizes required to detect reasonable treatment effects.",
keywords = "FEV, Forced expiratory flow rates, Longitudinal studies, Outcome assessment, Plethysmography",
author = "Davis, {Stephanie D.} and Margaret Rosenfeld and Kerby, {Gwendolyn S.} and Lyndia Brumback and Kloster, {Margaret H.} and Acton, {James D.} and Andrew Colin and Conrad, {Carol K.} and Hart, {Meeghan A.} and Hiatt, {Peter W.} and Mogayzel, {Peter J.} and Johnson, {Robin C.} and Wilcox, {Stephanie L.} and Castile, {Robert G.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1164/rccm.200908-1236OC",
language = "English",
volume = "182",
pages = "1387--1397",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "11",

}

TY - JOUR

T1 - Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints

AU - Davis, Stephanie D.

AU - Rosenfeld, Margaret

AU - Kerby, Gwendolyn S.

AU - Brumback, Lyndia

AU - Kloster, Margaret H.

AU - Acton, James D.

AU - Colin, Andrew

AU - Conrad, Carol K.

AU - Hart, Meeghan A.

AU - Hiatt, Peter W.

AU - Mogayzel, Peter J.

AU - Johnson, Robin C.

AU - Wilcox, Stephanie L.

AU - Castile, Robert G.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Rationale: The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures. Objectives: To evaluate safety, feasibility, and ability to detect abnormalities in lung function of serial pulmonary function tests (PFTs) in infants with CF. Methods:Multicenter observational study using a commercial device, rigorous training, ongoing quality control, and over-reading of data by an independent panel. Raised volume rapid thoracoabdominal compression technique and plethysmography were performed at enrollment and at 6 and 12 months, with an additional 1-month reproducibility visit. Measurements and Main Results: A total of 342 procedures were performed in 100 infants with CF at 10 centers. FRC measurements were acceptable at a higher proportion of study visits (89%) than raised volume (72%) or fractional lung volume (68%) measurements. Average Z scores for many parameters differed significantly from historical control values. Mean (95% confidence interval) Z scores were: -0.52 (-0.78 to -0.25) for forced expiratory flow at 75% (FEF75) for FVC; 1.92 (1.39-2.45) for FRC; 1.22 (0.68-1.76) for residual volume; 0.87 (0.60-1.13) for FRC/total lung capacity; and 0.66 (0.27-1.06) for residual volume/total lung capacity. For future multicenter clinical trials using infant PFTs as primary endpoints, minimum detectable treatment effects are presented for several sample sizes. Conclusions: In this 10-center study, key PFT measures were significantly different in infants with CF than in historical control subjects. However, infant PFTs do not yet appear ready as primary efficacy endpoints for multicenter clinical trials, particularly at inexperienced sites, based on acceptability rates, variability, and potentially large sample sizes required to detect reasonable treatment effects.

AB - Rationale: The conducting of clinical trials in infants with cystic fibrosis (CF) has been hindered by lack of sensitive outcome measures. Objectives: To evaluate safety, feasibility, and ability to detect abnormalities in lung function of serial pulmonary function tests (PFTs) in infants with CF. Methods:Multicenter observational study using a commercial device, rigorous training, ongoing quality control, and over-reading of data by an independent panel. Raised volume rapid thoracoabdominal compression technique and plethysmography were performed at enrollment and at 6 and 12 months, with an additional 1-month reproducibility visit. Measurements and Main Results: A total of 342 procedures were performed in 100 infants with CF at 10 centers. FRC measurements were acceptable at a higher proportion of study visits (89%) than raised volume (72%) or fractional lung volume (68%) measurements. Average Z scores for many parameters differed significantly from historical control values. Mean (95% confidence interval) Z scores were: -0.52 (-0.78 to -0.25) for forced expiratory flow at 75% (FEF75) for FVC; 1.92 (1.39-2.45) for FRC; 1.22 (0.68-1.76) for residual volume; 0.87 (0.60-1.13) for FRC/total lung capacity; and 0.66 (0.27-1.06) for residual volume/total lung capacity. For future multicenter clinical trials using infant PFTs as primary endpoints, minimum detectable treatment effects are presented for several sample sizes. Conclusions: In this 10-center study, key PFT measures were significantly different in infants with CF than in historical control subjects. However, infant PFTs do not yet appear ready as primary efficacy endpoints for multicenter clinical trials, particularly at inexperienced sites, based on acceptability rates, variability, and potentially large sample sizes required to detect reasonable treatment effects.

KW - FEV

KW - Forced expiratory flow rates

KW - Longitudinal studies

KW - Outcome assessment

KW - Plethysmography

UR - http://www.scopus.com/inward/record.url?scp=78649838472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649838472&partnerID=8YFLogxK

U2 - 10.1164/rccm.200908-1236OC

DO - 10.1164/rccm.200908-1236OC

M3 - Article

VL - 182

SP - 1387

EP - 1397

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 11

ER -